Tomoko Tamaki1, Yiqi Dong2, Yuko Ohno3, Tomotaka Sobue4, Hiroshi Nishimoto5, Akiko Shibata6. 1. Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Osaka, Japan. Electronic address: tamaki.tomoko.73e@st.kyoto-u.ac.jp. 2. Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Osaka, Japan. Electronic address: luckyer.tou17@sahs.med.osaka-u.ac.jp. 3. Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, 1-7 Yamadaoka, Suita 565-0871, Osaka, Japan. Electronic address: ohno@sahs.med.osaka-u.ac.jp. 4. Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan. Electronic address: tsobue@envi.med.osaka-u.ac.jp. 5. Division of Surveillance, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. Electronic address: hnishimo@ncc.go.jp. 6. Division of Surveillance, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. Electronic address: akshibat@ncc.go.jp.
Abstract
BACKGROUND: Despite the fact that rare cancer is a new target of cancer control in Japan, the incidence of rare cancers is unknown and there is no generally accepted definition of rare cancers in this country. With the aim of calculating incidences of rare cancers in Japan, we therefore adopted a definition and classification of rare cancers that had been published in the European Union (EU) in 2011. METHODS: Using incidence data between 1998 and 2007 submitted by 12 of population based cancer registries in Japan that met our quality criteria and drawing on the EU definition (incidence <6 per 100,000 per year), we estimated the incidences of 845 combinations of tumor sites and histological groups and thus identified the cancers that are rare in Japan. RESULTS: After identifying 193 combinations of tumor sites and histological groups that fit our criteria for rare cancers, we estimated their incidence to be about 75 per 100,000, which corresponds to about 94,800 new diagnoses in 2012 or approximately 15% of all cancer diagnoses. The categorization of rare and common cancers was almost the same in Japan as in EU. CONCLUSIONS: The present study provides an indication of the size of the rare cancer burden in Japan and epidemiological information to explore this. We are expecting further discussion based on our results with stakeholders in order to construct a Japanese definition of rare cancers.
BACKGROUND: Despite the fact that rare cancer is a new target of cancer control in Japan, the incidence of rare cancers is unknown and there is no generally accepted definition of rare cancers in this country. With the aim of calculating incidences of rare cancers in Japan, we therefore adopted a definition and classification of rare cancers that had been published in the European Union (EU) in 2011. METHODS: Using incidence data between 1998 and 2007 submitted by 12 of population based cancer registries in Japan that met our quality criteria and drawing on the EU definition (incidence <6 per 100,000 per year), we estimated the incidences of 845 combinations of tumor sites and histological groups and thus identified the cancers that are rare in Japan. RESULTS: After identifying 193 combinations of tumor sites and histological groups that fit our criteria for rare cancers, we estimated their incidence to be about 75 per 100,000, which corresponds to about 94,800 new diagnoses in 2012 or approximately 15% of all cancer diagnoses. The categorization of rare and common cancers was almost the same in Japan as in EU. CONCLUSIONS: The present study provides an indication of the size of the rare cancer burden in Japan and epidemiological information to explore this. We are expecting further discussion based on our results with stakeholders in order to construct a Japanese definition of rare cancers.
Authors: Sebastian Adeberg; Paul Windisch; Felix Ehret; Melissa Baur; Sati Akbaba; Thomas Held; Denise Bernhardt; Matthias F Haefner; Juergen Krauss; Steffen Kargus; Christian Freudlsperger; Peter Plinkert; Christa Flechtenmacher; Klaus Herfarth; Juergen Debus; Stefan Rieken Journal: Front Oncol Date: 2019-12-20 Impact factor: 6.244
Authors: Gemma A Bilkey; Richard W Trevithick; Emily P Coles; Jennifer Girschik; Kristen J Nowak Journal: BMC Cancer Date: 2021-07-08 Impact factor: 4.430